Abstract
Phase-I clinical studies of teraphtal and a "teraphtal + ascorbic acid" catalytic system have been completed. The dose-limiting toxicity and maximum tolerable dose were not reached even at the end of maximal dose trials. No side-effects characteristic of antitumor cytostatic drugs were registered. The gravest side-effect ever recorded was a collapse which could not be linked to teraphtal dosage and was probably caused by hypersensitivity to the drug. The drug was recommended for phase II trials.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Comparative Study
-
English Abstract
MeSH terms
-
Adrenal Gland Neoplasms / drug therapy
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms / drug therapy
-
Colonic Neoplasms / drug therapy
-
Female
-
Humans
-
Indoles / administration & dosage
-
Indoles / adverse effects
-
Indoles / therapeutic use*
-
Kidney Neoplasms / drug therapy
-
Male
-
Melanoma / drug therapy
-
Middle Aged
-
Sarcoma / drug therapy
-
Skin Neoplasms / drug therapy
-
Soft Tissue Neoplasms / drug therapy
Substances
-
Antineoplastic Agents
-
Indoles
-
theraphthal